1. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. (December 2018) Authors: McDermott, David; Huseni, Mahrukh; Atkins, Michael; Motzer, Robert; Rini, Brian; Escudier, Bernard; Fong, Lawrence; Joseph, Richard; Pal, Sumanta; Reeves, James; Sznol, Mario; Hainsworth, John; Rathmell, W.; Stadler, Walter; Hutson, Thomas; Gore, Martin; Ravaud, Alain; Bracarda, Sergio; Suárez, C... Journal: Nature medicine Issue: Volume 24:Number 12(2018) Page Start: 1941 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. (14th July 2020) Authors: Aeppli, Stefanie; Eboulet, Eric Innocents; Eisen, Tim; Escudier, Bernard; Fischer, Stefanie; Larkin, James; Gruenwald, Viktor; McDermott, David; Oldenburg, Jan; Omlin, Aurelius; Porta, Camillo; Rini, Brian; Schmidinger, Manuela; Sternberg, Cora; Rothermundt, Christian Journal: ESMO open Issue: Volume 5(2020)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 219 Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients. (10th December 2020) Authors: Tarhini, Ahmad; McDermott, David; Ambavane, Apoorva; Benedict, Agnes; Lee, Cho-Han; Ritchings, Corey; Stwalley, Brian; Regan, Meredith; Atkins, Michael Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 219 Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients. (9th November 2020) Authors: Tarhini, Ahmad; McDermott, David; Ambavane, Apoorva; Benedict, Agnes; Lee, Cho-Han; Ritchings, Corey; Stwalley, Brian; Regan, Meredith; Atkins, Michael Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial. (10th December 2020) Authors: Winer, Ira; Gilbert, Lucy; Vaishampayan, Ulka; Rosen, Seth; Hoimes, Christopher; Muzaffar, Jameel; Spreafico, Anna; McDermott, David; Chu, Quincy; Dumas, Olivier; Chauhan, Aman; Chaudhry, Arvind; Tomczak, Piotr; Boni, Valentina; Bruno, Debora; Curtis, Kelly; Wang, Yan; Dorn, Elizabeth; Rege, Jess... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A211 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2. (6th November 2014) Authors: Kaufman, Howard L; Aung, Sandra; Morse, Michael; Wong, Michael; Lowder, James; Daniels, Gregory; McDermott, David Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma—Analysis Using Diagnostic Nodes. (3rd August 2015) Authors: Rothermundt, Christian; Bailey, Alexandra; Cerbone, Linda; Eisen, Tim; Escudier, Bernard; Gillessen, Silke; Grünwald, Viktor; Larkin, James; McDermott, David; Oldenburg, Jan; Porta, Camillo; Rini, Brian; Schmidinger, Manuela; Sternberg, Cora; Putora, Paul M. Journal: Oncologist Issue: Volume 20:Number 9(2015) Page Start: 1028 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina; Bajaj, Anshika; Archer, Jacob; Reeves, Rebecca; Ngo, Lisa; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fuseri, Nicola... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina; Bajaj, Anshika; Archer, Jacob; Reeves, Rebecca; Ngo, Lisa; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fuseri, Nicola... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗